WO2008025945A1 - Fluidic indicator device - Google Patents

Fluidic indicator device Download PDF

Info

Publication number
WO2008025945A1
WO2008025945A1 PCT/GB2007/003091 GB2007003091W WO2008025945A1 WO 2008025945 A1 WO2008025945 A1 WO 2008025945A1 GB 2007003091 W GB2007003091 W GB 2007003091W WO 2008025945 A1 WO2008025945 A1 WO 2008025945A1
Authority
WO
WIPO (PCT)
Prior art keywords
flow path
liquid
assay device
test
region
Prior art date
Application number
PCT/GB2007/003091
Other languages
French (fr)
Inventor
David Tolley
Balbir Raj
Stephen Carlisle
Original Assignee
Inverness Medical Switzerland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inverness Medical Switzerland Gmbh filed Critical Inverness Medical Switzerland Gmbh
Priority to CA2661065A priority Critical patent/CA2661065C/en
Priority to CN200780038590.5A priority patent/CN101528350B/en
Priority to JP2009526157A priority patent/JP5263624B2/en
Priority to AU2007291058A priority patent/AU2007291058B2/en
Priority to EP07789214.9A priority patent/EP2056965B9/en
Publication of WO2008025945A1 publication Critical patent/WO2008025945A1/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5023Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures with a sample being transported to, and subsequently stored in an absorbent for analysis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • G01N33/54386Analytical elements
    • G01N33/54387Immunochromatographic test strips
    • G01N33/54388Immunochromatographic test strips based on lateral flow
    • G01N33/54389Immunochromatographic test strips based on lateral flow with bidirectional or multidirectional lateral flow, e.g. wherein the sample flows from a single, common sample application point into multiple strips, lanes or zones
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/76Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/06Fluid handling related problems
    • B01L2200/0621Control of the sequence of chambers filled or emptied
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/14Process control and prevention of errors
    • B01L2200/148Specific details about calibrations
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00Additional constructional details
    • B01L2300/02Identification, exchange or storage of information
    • B01L2300/025Displaying results or values with integrated means
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00Additional constructional details
    • B01L2300/06Auxiliary integrated devices, integrated components
    • B01L2300/0681Filter
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00Additional constructional details
    • B01L2300/08Geometry, shape and general structure
    • B01L2300/0809Geometry, shape and general structure rectangular shaped
    • B01L2300/0816Cards, e.g. flat sample carriers usually with flow in two horizontal directions
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00Additional constructional details
    • B01L2300/08Geometry, shape and general structure
    • B01L2300/0861Configuration of multiple channels and/or chambers in a single devices
    • B01L2300/0864Configuration of multiple channels and/or chambers in a single devices comprising only one inlet and multiple receiving wells, e.g. for separation, splitting
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00Moving or stopping fluids
    • B01L2400/04Moving fluids with specific forces or mechanical means
    • B01L2400/0403Moving fluids with specific forces or mechanical means specific forces
    • B01L2400/0406Moving fluids with specific forces or mechanical means specific forces capillary forces
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502723Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by venting arrangements
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502753Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by bulk separation arrangements on lab-on-a-chip devices, e.g. for filtration or centrifugation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/807Apparatus included in process claim, e.g. physical support structures

Definitions

  • the invention relates to a fluidic device for the passage of a liquid. It also relates to an assay device suitable for measurement of the amount and/or presence of. an analyte in, or property of, a fluid sample.
  • EP291194 discloses an assay device comprising a lateral flow porous carrier wherein accumulation of a particulate labelled binding reagent in a detection zone provides a visible signal to the user of the presence or absence of analyte in a liquid sample. The signal however requires interpretation by the user.
  • Digital devices have been developed as a consequence wherein on-board optics are able to measure the presence or intensity of the labelled reagent and provide an absolute answer which does not require interpretation. Digital devices however are expensive to produce as they require in addition to the optical components, a power source further processing electronics and a digital display.
  • US4963498 discloses a microfluidic device for the measurement of an analyte in, or property of a fluid sample wherein reagents present in the device affect the flow rate of the sample.
  • the device may comprise both a test capillary and a reference or control capillary.
  • EP456699 discloses an apparatus for testing the presence of a substance in a liquid comprising a sample application port connected to a number of fluid conduits upstream from respective indicator chambers. According to an example, agglutination reagents present in the fluid conduits interact with the sample in order to change its flow rate, for example, preventing the liquid from reaching an indicator chamber within the time frame of the assay.
  • a capillary device for testing for the presence of a substance is also disclosed by WO2004/083859.
  • the device works by causing agglutination of a liquid sample in a test capillary in the presence of an analyte of interest (typically, human chorionic gonadotrophin, hCG), which agglutination prevents the flow of liquid sample in the test capillary but not in a control capillary (which contains no agglutination reagents).
  • analyte of interest typically, human chorionic gonadotrophin, hCG
  • hCG human chorionic gonadotrophin
  • a problem associated with non-digital assay devices is that they provide an assay result as a signal of variable strength, which can require a degree of interpretation. This leaves the assay result open to misinterpretation, especially where the user or reader of the assay device has a preferred assay result in mind.
  • some testing devices such as a pregnancy- testing device
  • the present invention provides, in preferred embodiments a simpler method of providing a binary outcome assay device which is far simpler to produce than existing optical/electronic assay devices.
  • the invention provides a fluidic assay device for assaying at least one property of a liquid sample, the device comprising:
  • junction region at which the test flow path and the reference flow path contact one another, the junction region typically comprising an outlet, conduit, chamber or other portion which permits the onward flow of liquid;
  • the test flow path and/or the reference flow path may comprise or consist of a microfluidic channel, a porous carrier, or a combination of the two.
  • Preferred porous carriers include nitrocellulose and filter paper.
  • the microfluidic channel is preferably of capillary dimensions such that a typical sample liquid is able to flow along the channel by capillary flow.
  • the test and/or reference flow paths comprise or consist of channels having at least a portion with a capillary dimension.
  • Typical microfluidic channels have an internal cross-sectional dimension of between 0.1 and 500 ⁇ m, more typically between 1 and lOO ⁇ m.
  • the microfluidic channels may be formed from synthetic plastics materials such as polycarbonate, epoxy resin etc. , glass or metal.
  • the channels may be formed by etching, casting, moulding etc. using conventional techniques.
  • the property of the liquid sample which is assayed comprises the presence and/or amount of an analyte of interest.
  • the analyte of interest may comprise, for example, a steroid, a hormone, a peptide or ..polypeptide, a carbohydrate, a lipid, a lipoprotein, a polynucleotide, an enzyme, a blood group marker, a disease marker, a diagnostic or prognostic indicator, a cation, an anion, or a molecular complex such as a virus, bacterium, yeast, fungus, spore or eukaryotic cell.
  • the analyte of interest comprises hCG.
  • the analyte is glucose.
  • a property of a liquid sample that may be determined may be for example a coagulation property of blood or plasma such as prothombin time, partial activated thromboplastin time, thrombin time, and activated clotting time.
  • the assay device may comprise a control, wherein the control is capable of generating a signal which indicates that sample has been correctly applied to the sample application region and that the assay device is working normally.
  • the control may comprise a control flow path having one or more reagents therein.
  • the reference flow path may also act as a control.
  • control flow path is such that sample liquid applied to the sample application region will flow along the flow path and typically to an indicator region, either upstream or downstream of the junction region and there generate a signal, typically a visible signal.
  • the test flow path will generally be substantially similar in character to the reference flow path, but will typically comprise one or more reagents or binding partners which will react with or bind to the analyte of interest. Preferably such reaction or binding event has the effect of altering (typically decreasing) the rate of flow of sample liquid along the test flow path.
  • the device of the invention can readily be configured to assay for the presence and/or amount of two or more analytes of interest by providing a two or more test flow paths and, optionally, a corresponding number of reference flow paths.
  • a separate sample application port or input is provided in the sample application region for each test flow path.
  • the sample application region comprises a common sample application port or input, such that sample liquid applied thereto may flow into two or more flow paths (e.g. two or more test flow paths; or. at least a test flow path and a reference flow path).
  • the device comprises a common sample application port or input which supplies sample liquid to all flow paths present in the device, such that a single sample application step is sufficient to initiate the assay.
  • the liquid sample may be any suitable liquid, such as water, sewage sample, or an aqueous extract (e.g. an aqueous food or drink sample) or a biological sample e.g. blood, plasma, serum, urine, pus, sweat, saliva, vaginal fluid, or tears.
  • a preferred sample is urine.
  • the liquid sample may be applied to the device 'neat' or may be subjected to a pretreatment step (e.g. including one or more of the following: mixing; agitation; sonication; dilution; incubation; denaturation; or reaction with one or more reagents).
  • Performance of the assay conveniently comprises reacting or interacting the sample with one or more substances which have the capacity to affect the rate of flow of liquid sample along the test flow path in order to provide an indication or measure of the presence and/or amount of an analyte in, or other property of, the fluid sample.
  • the substances will be provided within the assay device, but additionally or alternatively one or more such substances may be mixed with the sample prior to application of the sample to the assay device.
  • reaction or interaction of the substance(s) with the sample will tend to alter (i.e. increase or decrease) the rate of progress of sample along the test flow path.
  • the substance(s) may be such as to increase the rate of flow of sample liquid along the test flow path if the sample comprises an analyte of interest above a certain ⁇ nimum detectable concentration. More preferably however the effects of the substance(s) are such as to impede or decrease the rate of flow of sample liquid along the test flow path if the sample comprises the analyte(s) of interest.
  • the device comprises one or more reagents which react with, or binding partners which bind to, the analyte(s) of interest.
  • Convenient binding partners comprise antibodies or antigen-binding fragments thereof (such as Fab, Fv, scFv, domain antibodies and the like), or multimers of antibodies or antigen-binding fragments thereof.
  • binding partners may comprise, for example, biotin, streptavidin, complementary polynucleotides (comprising
  • Receptors include both prokaryotic and eukaryotic polypeptides, numerous examples of which (both full length and truncated) are known.
  • the reagents or binding partners may be immobilised on the assay device (i.e. remain attached during performance of the assay) or may be releasably attached (i.e. are released from a support during performance of the assay), or may comprise a combination of immobilised and releasably attached reagents or binding partners.
  • a releasably attached binding partner is provided on a porous carrier located at an upstream portion of the test flow path.
  • an immobilised binding partner is provided in the test flow path.
  • a releasably attached binding partner is provided (on a porous carrier or otherwise) at a relatively upstream portion of the test flow path and an immobilised binding partner is provided at a relatively downstream portion of the test flow path.
  • Methods of releasably attaching or of immobilising antibodies and the like on surfaces are well known to those skilled in the art.
  • a binding partner is provided within a capillary channel forming part of the test flow path.
  • the binding partner or reagent may advantageously be labelled. Suitable labels include, but are not limited to, an enzyme, a fluorescent dye, a coloured dye and a particle of colloidal gold or other colloidal metal.
  • the presence of analyte may cause an increase in the flow rate of fluid in the test channel.
  • binding of an analyte may cause displacement of a species which is conjugated to a detergent, the presence of which in the fluid channel results in an increase in flow rate of the sample.
  • the binding partner is particulate or comprises a particulate substance.
  • the binding partner comprises a latex particle or a particle of colloidal gold or other metal.
  • the particle comprises a plurality of binding partner molecules, such that a single particle may simultaneously be bound to a plurality of members of the analyte of interest.
  • the latex particle is loaded or marked with a direct visual label, such as a coloured dye.
  • the binding partner or partners are such that an agglutination reaction occurs in the test flow path in the presence of the analyte of interest, which agglutination reaction serves to retard or inhibit the flow of sample liquid along the test flow path.
  • the effect of such retardation or inhibition of flow along the test flow path is that liquid flowing along the reference or control path will reach the junction region first, which in turn blocks the further advance of liquid along the test flow path (as explained below).
  • test flow path may comprise a reagent such as thromboplastin, or one or more of the various clotting factors, for the determination of a coagulation property of blood or plasma.
  • a reagent such as thromboplastin, or one or more of the various clotting factors, for the determination of a coagulation property of blood or plasma.
  • the reagent may be Concanavalin A which is able to react with glucose to cause an increase in viscosity in the fluid sample.
  • the test flow path may comprise a solvent swellable polymer gel which swells in me presence of a particular solvent to cause an increase in viscosity.
  • a dextran polymer when the analyte to be detected is water.
  • the assay device of the present invention can be thought of as using a "race” between the liquid flowing along the test flow path and that flowing along the reference flow path - the first liquid to reach the junction region will win the "race” and block further advance of liquid along the other flow path.
  • One way of forming the block is to provide a number (one or more) of vents downstream of the junction region. Displacement of the gas (typically air) filling the microfluidic channel of the test and flow paths, via these vents, is necessary to allow liquid to advance along the flow paths. However, once liquid from one of the flow paths has reached the junction it prevents the venting of gas from the other flow path, forming a gas block
  • test and reference flow paths may additionally comprise partial barriers to flow, such as constrictions, filters, weirs or the like, which encourage the formation of more total barriers or obstructions in the presence of e.g. an agglutination reaction.
  • partial barriers to flow such as constrictions, filters, weirs or the like, which encourage the formation of more total barriers or obstructions in the presence of e.g. an agglutination reaction.
  • a partial barrier or obstruction is provided in the one or more test flow paths but not in the reference flow path.
  • the device conveniently comprises at least one indicator region.
  • the indicator region comprises a display which displays information about the assay result to a person using the assay device. Typically the assay result is displayed, at least in part, by a colour change.
  • an indicator region downstream of the junction region.
  • dyes of different colours are provided in the respective test and control flow paths, such that the presence of a dye of a particular colour in the indicator region reveals by which route (the test or control flow path) liquid first reached the indicator region.
  • two different enzymes e.g. horseradish peroxidase and glucose oxidase
  • a respective substrate for one of the enzymes could be provided in the flow paths which, reacts, in the presence of the relevant enzyme catalyst, to produce a coloured product.
  • The. colour of the product reveals which substrate was introduced into the indicator region (and hence by which flow path liquid first arrived there).
  • the indicator region (if located downstream of the junction region) may comprise components of two different signal- generating means which generate detectably different signals, with one or more further components of each signal-generating means being mobilisably disposed upstream, the further component of one signal-generating means being disposed in the test flow path, and the further component of the other signal-generating means being disposed in the reference flow path, the further component being required to contact the other component in the indicator region in order to generate a signal.
  • Which of the two signal-generating means is activated depends on which of the further components reaches the indicator region first, which in turn depends on the relative rates of flow of liquid along the test and reference flow paths.
  • the indicator region comprises a pH-sensitive indicator
  • the test and reference flow paths each comprise a different pH-affecting agent e.g. one comprises a buffer at relatively acidic pH and one comprises a buffer at relatively alkaline pH.
  • the flow path by which liquid first reaches the indicator region will therefore determine the pH in the indicator region and hence the colour of the indicator.
  • Embodiments of this general type with a downstream indicator region, have the advantage that it is not necessary to impede or retard the flow of liquid along the test flow path by a large amount in order for the liquid flowing along the reference flow path to reach the indicator region first - a time differential of as little as 1 or 2 seconds will suffice.
  • an indicator region is provided, upstream of the junction region, in each of the reference and the test flow paths.
  • flow of liquid along the reference flow path to a certain point acts to block flow of liquid along the test flow path before the liquid reaches the indicator region on the test flow path, such that a certain assay result is displayed in the indicator region.
  • an indicator substance such as a dye
  • upstream of the indicator region such that a visible change can be seen if/when liquid reaches the indicator region of the test and/or reference-)- flow paths.
  • the indicator region comprises a microfluidic channel, such as a capillary, which is visible to a user (e.g. through a window or aperture in an otherwise opaque housing).
  • the indicator region comprises two channels or capillaries, one forming part of the test flow path and one forming part of the reference flow path.
  • the microfluidic channels or capillaries in the indicator region became filled with a coloured liquid during performance of the assay.
  • the colour of the liquid may itself indicate the result of the assay.
  • the coloured liquid may simply serve to alter the visibility of the channel or capillary. For example, a clear plastics or glass capillary against a clear or white background may not be readily apparent.
  • a coloured liquid into such a channel or capillary will increase contrast and render the channel or capillary readily visible.
  • the channel or capillary is initially of high contrast with its background (e.g. a white capillary against a red background)
  • introduction of a coloured liquid into the channel or capillary which is of the same colour as the background will reduce the contrast and render the capillary or channel difficult to observe.
  • the indicator region may comprise one or more channels or capillaries which form one or more words or symbols (such as "PREGNANT", or a plus or minus symbol).
  • one flow path comprises an indicator region in which a channel or capillary forms the word "NOT”
  • another flow path comprises an indicator region in which a channel or capillary forms the word "PREGNANT”.
  • the word “NOT” is formed in the test flow path
  • the word “PREGNANT” is formed in the reference flow path. If a sample is applied the device which does not contain any hCG (i.e. the subject is not pregnant), liquid is free to flow along both the test and reference flow paths.
  • a coloured label e.g. a dye
  • a coloured label e.g. a dye
  • agglutination reagents e.g. particles of latex coated with anti-hCG antibodies
  • the assay device it may be preferred to bias the assay device, so as to configure the device such that liquid flowing along the reference flow path will, in the absence of analyte of interest in the sample, reach the junction region slightly before the liquid flowing along the test flow path.
  • This feature applies particularly, but not exclusively, to those embodiments in which an indicator region is provided downstream of the junction region, and in which, for example, the test and reference flow paths are provided with a respective indicator or label. If the times taken for the liquid sample to reach the junction region via the reference flow path and the test flow path were identical, it is at least conceivable that liquid from both flow paths would reach the junction region exactly simultaneously and hence become mixed in the indicator region, which would fail to provide a clear assay result. This can be avoided by making the reference flow path shorter and/or by making the rate of flow along the reference flow path more rapid (e.g. by using a thinner bore capillary).
  • the invention provides a method of testing for the presence of an analyte of interest in a liquid sample, the method comprising the step of applying the liquid sample to the sample application region of a device in accordance with the first aspect of the invention; and noting or recording the assay result displayed by the device.
  • the invention provides a method of making an assay device in accordance with the first aspect of the invention, comprising assembling the necessary elements in an operable relationship.
  • FIGS 1 and 2 show schematic representations of different embodiments of an assay device in accordance with the present invention.
  • Figure 1 shows a device according to .the invention.
  • the device has a sample application region 2 fmidicaUy connected to test flow path 4 and a reference flow path 6, which both comprise a capillary channel.
  • a filter 8 may optionally be provided in one or both of the flow paths.
  • the flow paths converge downstream at a junction region 10 leading to a common channel 12.
  • An indicator region 14 may be provided downstream from the junction region 10.
  • Liquid sample applied to the device via a sample application port in the sample application region 2 is able to flow respectively along the test and reference flow paths 4, 6 and towards the junction region 10.
  • One or more vents are provided in the common channel 12 and the indicator region 14 to allow air to be displaced from the device by the advance of liquid along the capillaries. However, once one of the fluid fronts has reached the junction region 10, it blocks off the other flow path from the vents, preventing further advance of the liquid along the other flow path.
  • An indication means may be provided in the fluid channels to enable an observer to determine which fluid in the respective channel arrived first.
  • dyes of different colours may be provided in each channel such that the fluid sample is able to interact with the dye to produce liquid of a particular colour.
  • the presence of a particular coloured dye in the indicator region would enable a user to determine which fluid reached the fluid gate first.
  • a base layer was prepared from agarose coated 200 ⁇ m polyester (GelBond, BMA).
  • the appropriate microfluidic features were cut out of a 75 ⁇ m thick heat sealing adhesive PE layers using a GraftTeC cutter and the two layers laminated together.
  • Finally a third layer was laminated to the intermediate layer to provide microfluidic channels of 75 ⁇ m.
  • the assay device comprises a sample application port in a common sample application region 2, from which liquid sample can flow into a capillary forming part of the test flow path 4 and a separate capillary forming part of the reference flow path 6.
  • each flow path may be provided with a unique, separate sample application region.
  • the assay device described in the present examples may be provided with further test flow paths to test for the presence of further analytes of interest.
  • the or each further test flow path can, if desired, be provided with a corresponding reference flow path.
  • each flow path comprises a filter element 8 and an indicator region 14, upstream of a junction region 10.
  • the filer element 8 comprises one or more binding partners for the analyte of interest, in this instance hCG.
  • the binding partner particles coated with anti-hCG monoclonal antibody, mediates an agglutination reaction.
  • Each flow path is also provided with a coloured dye which is mobilised by contact, and migrates, with the liquid sample.
  • the indicator region 14 of each flow path comprises a capillary channel forming the word "NOT” in the test flow path 4 and the word “PREGNANT” in the reference flow path.
  • These capillaries are formed from clear synthetic plastics material and are against a low contrast background (e.g. white or clear synthetic plastics material). Accordingly, prior to performance of the assay, the capillaries are not highly visible.
  • Vents may be provided at several points along the reference flow path to encourage the flow of liquid therealong. In particular these vents may be provided to assist the liquid in filling the indicator region of the reference flow path.
  • vents in the test flow path air being vented from the test flow path capillary 4 only via one or more vents downstream of the junction region 10, in the common channel 12, such that if liquid flowing along the reference flow path 6 reaches the junction region 10 before the liquid front flowing along the test flow path 4, air can no longer be displaced from the test flow path capillary and further advance of the liquid along that channel is prevented.
  • the rate of flow of liquid along the test and reference flow paths, and/or the length of the respective flow paths, is adjusted such that, in the absence of hCG, liquid flows along both flow paths 4, 6 and fills the respective indicator regions.
  • the liquid flowing along the reference flow path will reach the junction region 10 either simultaneously with the liquid flowing along the test flow path or just 1 or 2 seconds in advance thereof.
  • the applied sample comprises hCG
  • agglutination will take place in the test flow path 4 which substantially retards the advance of liquid along the test flow path capillary towards the indicator region. This allows liquid flowing along the reference flow path to "win the race” to the junction region easily.
  • the liquid flowing along the reference flow path reaches the junction region 10 before the liquid flowing along the test flow path 4 reaches the indicator region.
  • the word “NOT” does not become filled with dye and remains indistinct, whilst the word “PREGNANT” becomes highly visible and thus displays the assay result.
  • a microfluidic device was prepared having a sample application port provided upstream from a fluid channel of dimensions, 5mm wide by 3cm long by lOO ⁇ m in height. Provided at a distance of 2cm along the fluid channel was a filter zone of 5mm in length comprising channels running parallel to the fluid channel having a 30 ⁇ m gap.
  • test solution took 60s to reach the end of the channel.
  • reference fluid took just 10s.
  • the delay in flow of the test fluid was due to the agglutinated particles becoming stuck in the filter zone. In the case of the reference fluid, no agglutination took place and therefore the fluid is able to flow unimpeded.

Abstract

Disclosed is a fluidic assay device for assaying at least one property of a liquid sample, the device comprising: (i) a liquid sample application region (2); (ii) at least one test flow path in liquid flow communication with the sample application region (4); (iii) a reference flow path in liquid flow communication with the sample application region (6); and (iv) a junction region (10), at which the test flow path and the reference flow path contact one another, the junction region typically comprising an outlet, conduit, chamber or other portion which permits the onward flow of liquid; wherein a liquid flowing along the reference flow path, upon reaching the junction region, has the effect of preventing the flow of liquid along the test flow path.

Description

Fluidic Indicator Device
Field of the Invention
The invention relates to a fluidic device for the passage of a liquid. It also relates to an assay device suitable for measurement of the amount and/or presence of. an analyte in, or property of, a fluid sample.
Background of the invention
Simple disposable fluidic devices for the detection of an analyte are known. EP291194 discloses an assay device comprising a lateral flow porous carrier wherein accumulation of a particulate labelled binding reagent in a detection zone provides a visible signal to the user of the presence or absence of analyte in a liquid sample. The signal however requires interpretation by the user. Digital devices have been developed as a consequence wherein on-board optics are able to measure the presence or intensity of the labelled reagent and provide an absolute answer which does not require interpretation. Digital devices however are expensive to produce as they require in addition to the optical components, a power source further processing electronics and a digital display.
US4963498 discloses a microfluidic device for the measurement of an analyte in, or property of a fluid sample wherein reagents present in the device affect the flow rate of the sample. The device may comprise both a test capillary and a reference or control capillary.
EP456699 discloses an apparatus for testing the presence of a substance in a liquid comprising a sample application port connected to a number of fluid conduits upstream from respective indicator chambers. According to an example, agglutination reagents present in the fluid conduits interact with the sample in order to change its flow rate, for example, preventing the liquid from reaching an indicator chamber within the time frame of the assay. A capillary device for testing for the presence of a substance is also disclosed by WO2004/083859. The device works by causing agglutination of a liquid sample in a test capillary in the presence of an analyte of interest (typically, human chorionic gonadotrophin, hCG), which agglutination prevents the flow of liquid sample in the test capillary but not in a control capillary (which contains no agglutination reagents). The presence or absence of liquid sample at downstream portions of the test and control capillaries is detected by electrodes.
A problem associated with non-digital assay devices, especially pregnancy-testing devices and/or home-use assay devices, is that they provide an assay result as a signal of variable strength, which can require a degree of interpretation. This leaves the assay result open to misinterpretation, especially where the user or reader of the assay device has a preferred assay result in mind. In the case of some testing devices however, such as a pregnancy- testing device, it is preferred to configure the device such that no interpretation is required and the assay result is provided as one of two alternatives (i.e. pregnant or not pregnant). This may be described as a "binary outcome" device. This provides an unequivocal result which removes the need for interpretation by the user, which is undesirable. This problem has been addressed in the prior art by the provision of assay devices or assay device readers incorporating complicated optical and electronic components to read a variable strength signal and then provide a binary outcome via an electronic (e.g. LCD or LED) display. The present invention provides, in preferred embodiments a simpler method of providing a binary outcome assay device which is far simpler to produce than existing optical/electronic assay devices.
Summary of the Invention
In a first aspect the invention provides a fluidic assay device for assaying at least one property of a liquid sample, the device comprising:
(i) a liquid sample application region; (ii) at least one test flow path in liquid flow communication with the sample application region;
(iii) a reference path in liquid flow communication with the sample application region; and
(iv) a junction region, at which the test flow path and the reference flow path contact one another, the junction region typically comprising an outlet, conduit, chamber or other portion which permits the onward flow of liquid;
wherein a liquid flowing along the reference flow path, upon reaching the junction region, has the effect of preventing the flow of liquid along the test flow path.
Conversely, in the event that liquid flowing along the test flow path reaches the "* junction region before liquid from the reference flow path it is possible, at least in some embodiments, that the flow of liquid along the reference flow path may be prevented. Prevention of the flow of liquid along the reference or test flow path is not necessarily permanent: it is sufficient for the flow of liquid to be prevented within the timescale in which the assay is performed and read.
The test flow path and/or the reference flow path may comprise or consist of a microfluidic channel, a porous carrier, or a combination of the two. Preferred porous carriers include nitrocellulose and filter paper. The microfluidic channel is preferably of capillary dimensions such that a typical sample liquid is able to flow along the channel by capillary flow. Preferably the test and/or reference flow paths comprise or consist of channels having at least a portion with a capillary dimension.
Typical microfluidic channels have an internal cross-sectional dimension of between 0.1 and 500μm, more typically between 1 and lOOμm. The microfluidic channels may be formed from synthetic plastics materials such as polycarbonate, epoxy resin etc. , glass or metal. The channels may be formed by etching, casting, moulding etc. using conventional techniques.
Typically, but not necessarily, the property of the liquid sample which is assayed comprises the presence and/or amount of an analyte of interest. The analyte of interest may comprise, for example, a steroid, a hormone, a peptide or ..polypeptide, a carbohydrate, a lipid, a lipoprotein, a polynucleotide, an enzyme, a blood group marker, a disease marker, a diagnostic or prognostic indicator, a cation, an anion, or a molecular complex such as a virus, bacterium, yeast, fungus, spore or eukaryotic cell. In one preferred embodiment the analyte of interest comprises hCG. In another embodiment, the analyte is glucose. A property of a liquid sample that may be determined may be for example a coagulation property of blood or plasma such as prothombin time, partial activated thromboplastin time, thrombin time, and activated clotting time.
The assay device may comprise a control, wherein the control is capable of generating a signal which indicates that sample has been correctly applied to the sample application region and that the assay device is working normally. The control may comprise a control flow path having one or more reagents therein. The reference flow path may also act as a control.
Conveniently the control flow path is such that sample liquid applied to the sample application region will flow along the flow path and typically to an indicator region, either upstream or downstream of the junction region and there generate a signal, typically a visible signal.
The test flow path will generally be substantially similar in character to the reference flow path, but will typically comprise one or more reagents or binding partners which will react with or bind to the analyte of interest. Preferably such reaction or binding event has the effect of altering (typically decreasing) the rate of flow of sample liquid along the test flow path. The device of the invention can readily be configured to assay for the presence and/or amount of two or more analytes of interest by providing a two or more test flow paths and, optionally, a corresponding number of reference flow paths.
In one embodiment, a separate sample application port or input is provided in the sample application region for each test flow path. In another embodiment the sample application region comprises a common sample application port or input, such that sample liquid applied thereto may flow into two or more flow paths (e.g. two or more test flow paths; or. at least a test flow path and a reference flow path). Preferably the device comprises a common sample application port or input which supplies sample liquid to all flow paths present in the device, such that a single sample application step is sufficient to initiate the assay.
The liquid sample may be any suitable liquid, such as water, sewage sample, or an aqueous extract (e.g. an aqueous food or drink sample) or a biological sample e.g. blood, plasma, serum, urine, pus, sweat, saliva, vaginal fluid, or tears. A preferred sample is urine. The liquid sample may be applied to the device 'neat' or may be subjected to a pretreatment step (e.g. including one or more of the following: mixing; agitation; sonication; dilution; incubation; denaturation; or reaction with one or more reagents).
Performance of the assay conveniently comprises reacting or interacting the sample with one or more substances which have the capacity to affect the rate of flow of liquid sample along the test flow path in order to provide an indication or measure of the presence and/or amount of an analyte in, or other property of, the fluid sample. Preferably at least one of the substances will be provided within the assay device, but additionally or alternatively one or more such substances may be mixed with the sample prior to application of the sample to the assay device. Generally, reaction or interaction of the substance(s) with the sample will tend to alter (i.e. increase or decrease) the rate of progress of sample along the test flow path. The substance(s) may be such as to increase the rate of flow of sample liquid along the test flow path if the sample comprises an analyte of interest above a certain πήnimum detectable concentration. More preferably however the effects of the substance(s) are such as to impede or decrease the rate of flow of sample liquid along the test flow path if the sample comprises the analyte(s) of interest.
In a preferred embodiment the device comprises one or more reagents which react with, or binding partners which bind to, the analyte(s) of interest. Convenient binding partners comprise antibodies or antigen-binding fragments thereof (such as Fab, Fv, scFv, domain antibodies and the like), or multimers of antibodies or antigen-binding fragments thereof.
Other suitable binding partners (depending on the nature of the analyte of interest) may comprise, for example, biotin, streptavidin, complementary polynucleotides (comprising
10 or more, preferably 17 or more, bases of DNA, RNA, PNA, LNA or any combination thereof, optionally including modified or non-naturally occurring bases), and polypeptide receptors or at least portions thereof which retain binding activity for their respective ligand. Receptors include both prokaryotic and eukaryotic polypeptides, numerous examples of which (both full length and truncated) are known.
The reagents or binding partners may be immobilised on the assay device (i.e. remain attached during performance of the assay) or may be releasably attached (i.e. are released from a support during performance of the assay), or may comprise a combination of immobilised and releasably attached reagents or binding partners. For example, in one embodiment, a releasably attached binding partner is provided on a porous carrier located at an upstream portion of the test flow path. In another embodiment an immobilised binding partner is provided in the test flow path. In yet another embodiment a releasably attached binding partner is provided (on a porous carrier or otherwise) at a relatively upstream portion of the test flow path and an immobilised binding partner is provided at a relatively downstream portion of the test flow path. Methods of releasably attaching or of immobilising antibodies and the like on surfaces are well known to those skilled in the art. Conveniently a binding partner is provided within a capillary channel forming part of the test flow path. The binding partner or reagent may advantageously be labelled. Suitable labels include, but are not limited to, an enzyme, a fluorescent dye, a coloured dye and a particle of colloidal gold or other colloidal metal.
According to an embodiment, the presence of analyte may cause an increase in the flow rate of fluid in the test channel. For example binding of an analyte may cause displacement of a species which is conjugated to a detergent, the presence of which in the fluid channel results in an increase in flow rate of the sample.
Conveniently the binding partner is particulate or comprises a particulate substance. In one embodiment the binding partner comprises a latex particle or a particle of colloidal gold or other metal. Advantageously the particle comprises a plurality of binding partner molecules, such that a single particle may simultaneously be bound to a plurality of members of the analyte of interest. Preferably the latex particle is loaded or marked with a direct visual label, such as a coloured dye.
In an embodiment the binding partner or partners are such that an agglutination reaction occurs in the test flow path in the presence of the analyte of interest, which agglutination reaction serves to retard or inhibit the flow of sample liquid along the test flow path. The effect of such retardation or inhibition of flow along the test flow path is that liquid flowing along the reference or control path will reach the junction region first, which in turn blocks the further advance of liquid along the test flow path (as explained below).
In a further embodiment, the test flow path may comprise a reagent such as thromboplastin, or one or more of the various clotting factors, for the determination of a coagulation property of blood or plasma.
According to a further embodiment, the reagent may be Concanavalin A which is able to react with glucose to cause an increase in viscosity in the fluid sample. The test flow path may comprise a solvent swellable polymer gel which swells in me presence of a particular solvent to cause an increase in viscosity. An example of such is a dextran polymer when the analyte to be detected is water.
The assay device of the present invention can be thought of as using a "race" between the liquid flowing along the test flow path and that flowing along the reference flow path - the first liquid to reach the junction region will win the "race" and block further advance of liquid along the other flow path.
One way of forming the block is to provide a number (one or more) of vents downstream of the junction region. Displacement of the gas (typically air) filling the microfluidic channel of the test and flow paths, via these vents, is necessary to allow liquid to advance along the flow paths. However, once liquid from one of the flow paths has reached the junction it prevents the venting of gas from the other flow path, forming a gas block
(typically an air block), preventing liquid advancing along the blocked flow path. This arrangement is extremely simple, requires no moving parts, and is easy to manufacture.
One or both of the test and reference flow paths may additionally comprise partial barriers to flow, such as constrictions, filters, weirs or the like, which encourage the formation of more total barriers or obstructions in the presence of e.g. an agglutination reaction. Typically such a partial barrier or obstruction is provided in the one or more test flow paths but not in the reference flow path.
The device conveniently comprises at least one indicator region. In one embodiment there is an indicator region located downstream of the junction region. In one embodiment there is an indicator region located upstream of the junction region. In one embodiment there is an indicator region in or on the test flow path and an indicator region in or on the reference flow path, both indicator regions being located between the sample application region and the junction region. The indicator region comprises a display which displays information about the assay result to a person using the assay device. Typically the assay result is displayed, at least in part, by a colour change.
There are a great many ways by which a colour change, visible in the indicator region or regions of the device, could be effected.
In one example, there is an indicator region downstream of the junction region. In a simple embodiment, dyes of different colours are provided in the respective test and control flow paths, such that the presence of a dye of a particular colour in the indicator region reveals by which route (the test or control flow path) liquid first reached the indicator region. Alternatively, two different enzymes (e.g. horseradish peroxidase and glucose oxidase) could be provided in the indicator region, and a respective substrate for one of the enzymes could be provided in the flow paths which, reacts, in the presence of the relevant enzyme catalyst, to produce a coloured product. The. colour of the product reveals which substrate was introduced into the indicator region (and hence by which flow path liquid first arrived there). In general terms, the indicator region (if located downstream of the junction region) may comprise components of two different signal- generating means which generate detectably different signals, with one or more further components of each signal-generating means being mobilisably disposed upstream, the further component of one signal-generating means being disposed in the test flow path, and the further component of the other signal-generating means being disposed in the reference flow path, the further component being required to contact the other component in the indicator region in order to generate a signal. Which of the two signal-generating means is activated depends on which of the further components reaches the indicator region first, which in turn depends on the relative rates of flow of liquid along the test and reference flow paths.
In one embodiment, the indicator region comprises a pH-sensitive indicator, and the test and reference flow paths each comprise a different pH-affecting agent e.g. one comprises a buffer at relatively acidic pH and one comprises a buffer at relatively alkaline pH. The flow path by which liquid first reaches the indicator region will therefore determine the pH in the indicator region and hence the colour of the indicator.
Embodiments of this general type, with a downstream indicator region, have the advantage that it is not necessary to impede or retard the flow of liquid along the test flow path by a large amount in order for the liquid flowing along the reference flow path to reach the indicator region first - a time differential of as little as 1 or 2 seconds will suffice.
In other embodiments an indicator region is provided, upstream of the junction region, in each of the reference and the test flow paths. In one embodiment, flow of liquid along the reference flow path to a certain point acts to block flow of liquid along the test flow path before the liquid reaches the indicator region on the test flow path, such that a certain assay result is displayed in the indicator region. In some embodiments it may be advantageous to provide an indicator substance, such as a dye, upstream of the indicator region, such that a visible change can be seen if/when liquid reaches the indicator region of the test and/or reference-)- flow paths.
In some embodiments, the indicator region comprises a microfluidic channel, such as a capillary, which is visible to a user (e.g. through a window or aperture in an otherwise opaque housing). In one embodiment the indicator region comprises two channels or capillaries, one forming part of the test flow path and one forming part of the reference flow path. In one embodiment, the microfluidic channels or capillaries in the indicator region became filled with a coloured liquid during performance of the assay. The colour of the liquid may itself indicate the result of the assay. Alternatively, the coloured liquid may simply serve to alter the visibility of the channel or capillary. For example, a clear plastics or glass capillary against a clear or white background may not be readily apparent. Introduction of a coloured liquid into such a channel or capillary will increase contrast and render the channel or capillary readily visible. Alternatively, if the channel or capillary is initially of high contrast with its background (e.g. a white capillary against a red background), then introduction of a coloured liquid into the channel or capillary which is of the same colour as the background will reduce the contrast and render the capillary or channel difficult to observe. These all represent different methods of conveying or displaying a visible signal concerning the outcome of the assay.
In some embodiments, the indicator region may comprise one or more channels or capillaries which form one or more words or symbols (such as "PREGNANT", or a plus or minus symbol). In one particular embodiment, in which an assay device in accordance with the invention is provided as a pregnancy test device, one flow path comprises an indicator region in which a channel or capillary forms the word "NOT", and another flow path comprises an indicator region in which a channel or capillary forms the word "PREGNANT". Typically the word "NOT" is formed in the test flow path and the word "PREGNANT" is formed in the reference flow path. If a sample is applied the device which does not contain any hCG (i.e. the subject is not pregnant), liquid is free to flow along both the test and reference flow paths. A coloured label e.g. a dye, is transported along both flow paths, making the words "NOT" and "PREGNANT" appear as a message in a display. If a sample comprising hCG is applied to the device, agglutination reagents (e.g. particles of latex coated with anti-hCG antibodies) present in the test flow path reduce the rate of flow so much that liquid in the reference flow path reaches the junction before the liquid in the test flow path can reach the indicator region. This effectively blocks the test flow path, so that the word "NOT" does not become visible and instead the display gives the message "PREGNANT".
In some embodiments it may be preferred to bias the assay device, so as to configure the device such that liquid flowing along the reference flow path will, in the absence of analyte of interest in the sample, reach the junction region slightly before the liquid flowing along the test flow path. This feature applies particularly, but not exclusively, to those embodiments in which an indicator region is provided downstream of the junction region, and in which, for example, the test and reference flow paths are provided with a respective indicator or label. If the times taken for the liquid sample to reach the junction region via the reference flow path and the test flow path were identical, it is at least conceivable that liquid from both flow paths would reach the junction region exactly simultaneously and hence become mixed in the indicator region, which would fail to provide a clear assay result. This can be avoided by making the reference flow path shorter and/or by making the rate of flow along the reference flow path more rapid (e.g. by using a thinner bore capillary).
In a second aspect the invention provides a method of testing for the presence of an analyte of interest in a liquid sample, the method comprising the step of applying the liquid sample to the sample application region of a device in accordance with the first aspect of the invention; and noting or recording the assay result displayed by the device.
In a third aspect the invention provides a method of making an assay device in accordance with the first aspect of the invention, comprising assembling the necessary elements in an operable relationship.
For the avoidance of doubt it is hereby expressly stated that any features described herein as "preferred", "advantageous", "desirable", "convenient", "typical" or the like may be present in the invention in isolation or in combination with any other feature so described, unless the context dictates otherwise.
The invention will now be further described by way of illustrative example and with reference to the accompanying drawings, in which
Figures 1 and 2 show schematic representations of different embodiments of an assay device in accordance with the present invention.
EXAMPLES
Example 1
Figure 1 shows a device according to .the invention. The device has a sample application region 2 fmidicaUy connected to test flow path 4 and a reference flow path 6, which both comprise a capillary channel. A filter 8 may optionally be provided in one or both of the flow paths. The flow paths converge downstream at a junction region 10 leading to a common channel 12. An indicator region 14 may be provided downstream from the junction region 10.
Liquid sample applied to the device via a sample application port in the sample application region 2 is able to flow respectively along the test and reference flow paths 4, 6 and towards the junction region 10. One or more vents are provided in the common channel 12 and the indicator region 14 to allow air to be displaced from the device by the advance of liquid along the capillaries. However, once one of the fluid fronts has reached the junction region 10, it blocks off the other flow path from the vents, preventing further advance of the liquid along the other flow path. Thus the device only allows for the arrival in the indicator region 14 of fluid flowing along the flow path whose fluid front first reaches the junction region 10. An indication means may be provided in the fluid channels to enable an observer to determine which fluid in the respective channel arrived first. For example dyes of different colours may be provided in each channel such that the fluid sample is able to interact with the dye to produce liquid of a particular colour. Thus the presence of a particular coloured dye in the indicator region would enable a user to determine which fluid reached the fluid gate first.
Preparation of the assay device according to Fig 1. A base layer was prepared from agarose coated 200μm polyester (GelBond, BMA). The appropriate microfluidic features were cut out of a 75μm thick heat sealing adhesive PE layers using a GraftTeC cutter and the two layers laminated together. Finally a third layer was laminated to the intermediate layer to provide microfluidic channels of 75μm.
Example 2
An alternative embodiment of an assay device in accordance with the invention is illustrated in Figure 2. Components functionally equivalent to those of the embodiment illustrated in Figure 1 are denoted by common reference numerals.
As in the previous example, the assay device comprises a sample application port in a common sample application region 2, from which liquid sample can flow into a capillary forming part of the test flow path 4 and a separate capillary forming part of the reference flow path 6. Alternatively each flow path may be provided with a unique, separate sample application region. Those skilled in the art will appreciate that the assay device described in the present examples may be provided with further test flow paths to test for the presence of further analytes of interest. The or each further test flow path can, if desired, be provided with a corresponding reference flow path.
In the embodiment depicted in Figure 2, each flow path comprises a filter element 8 and an indicator region 14, upstream of a junction region 10.
The filer element 8 comprises one or more binding partners for the analyte of interest, in this instance hCG. In the presence of the analyte of interest the binding partner, particles coated with anti-hCG monoclonal antibody, mediates an agglutination reaction.
Each flow path is also provided with a coloured dye which is mobilised by contact, and migrates, with the liquid sample.
The indicator region 14 of each flow path comprises a capillary channel forming the word "NOT" in the test flow path 4 and the word "PREGNANT" in the reference flow path. These capillaries are formed from clear synthetic plastics material and are against a low contrast background (e.g. white or clear synthetic plastics material). Accordingly, prior to performance of the assay, the capillaries are not highly visible.
However, once the assay is initiated, the dye located in the flow paths upstream of the indicator region is mobilised by the advancing liquid sample. If the sample does not contain hCG, liquid is free to flow along both flow paths. The dye-containing liquid thus fills both capillaries, displaying the assay result "NOT PREGNANT". Vents may be provided at several points along the reference flow path to encourage the flow of liquid therealong. In particular these vents may be provided to assist the liquid in filling the indicator region of the reference flow path. Preferably there are no such vents in the test flow path, air being vented from the test flow path capillary 4 only via one or more vents downstream of the junction region 10, in the common channel 12, such that if liquid flowing along the reference flow path 6 reaches the junction region 10 before the liquid front flowing along the test flow path 4, air can no longer be displaced from the test flow path capillary and further advance of the liquid along that channel is prevented.
The rate of flow of liquid along the test and reference flow paths, and/or the length of the respective flow paths, is adjusted such that, in the absence of hCG, liquid flows along both flow paths 4, 6 and fills the respective indicator regions. Typically, in the absence of hCG in the sample, the liquid flowing along the reference flow path will reach the junction region 10 either simultaneously with the liquid flowing along the test flow path or just 1 or 2 seconds in advance thereof. r
If however the applied sample comprises hCG, agglutination will take place in the test flow path 4 which substantially retards the advance of liquid along the test flow path capillary towards the indicator region. This allows liquid flowing along the reference flow path to "win the race" to the junction region easily. The liquid flowing along the reference flow path reaches the junction region 10 before the liquid flowing along the test flow path 4 reaches the indicator region. In this instance, the word "NOT" does not become filled with dye and remains indistinct, whilst the word "PREGNANT" becomes highly visible and thus displays the assay result.
Example 3
In order to provide a practical demonstration of the feasibility of the invention 15μm polystyrene beads (Polysciences) were coated with aminodextran 500,000 RMM, then with NHS-LCLC-Biotin to prepare biotinylated latex beads (NHS = N-hydroxy succinimidyl, LCLC = "long chain", i.e. a 12 carbon spacer). Into 50 μl of a 200 μg/ml solution of BSA (to block non-specific binding sites), was added 50 μl of a 5% solution of the 15 μm biotin particles, mixed on a vortex. To the biotinylated particle solution in BSA, 5μl of streptavidin lμm magnetic particle in solution were added solution, while mixing on a vortex to prepare a test fluid. Immediately after preparation, the fluid was added to a microfluidic device as described below. A reference fluid consisting of BSA buffer was also prepared.
A microfluidic device was prepared having a sample application port provided upstream from a fluid channel of dimensions, 5mm wide by 3cm long by lOOμm in height. Provided at a distance of 2cm along the fluid channel was a filter zone of 5mm in length comprising channels running parallel to the fluid channel having a 30μm gap.
Two such devices were prepared and a test solution and reference solution were added respectively to both and the time taken for the fluid front to reach the end of the fluid channel was measured. In this particular example, the test solution took 60s to reach the end of the channel. In contrast, the reference fluid took just 10s.
The delay in flow of the test fluid was due to the agglutinated particles becoming stuck in the filter zone. In the case of the reference fluid, no agglutination took place and therefore the fluid is able to flow unimpeded.

Claims

1. A fluidic assay device for assaying at least one property of a liquid sample, the device comprising:
(i) a liquid sample application region;
(ii) at least one test flow path in liquid flow communication with the sample application region;
(iii) a reference flow path in liquid flow communication with the sample application region; and
(iv) a junction region, at which the test flow path and the reference flow path contact one another, the junction region typically comprising an outlet, conduit, chamber or other portion which permits the onward flow of liquid;
wherein a liquid flowing along the reference flow path, upon reaching the junction region, has the effect of preventing the flow of liquid along the test flow path.
2. An assay device according to claim 1, wherein the test and/or reference flow paths comprise a microfluidic channel, a porous carrier, or a combination of both.
3. An assay device according to claim 2, wherein the microfluidic channel comprises at least a portion which is of a capillary dimension.
4. An assay device according to any one of claims 1, 2 or 3, wherein the test and/or reference flow paths comprise one or more of the following: a filter; an incubation region; a chamber; a flow restriction.
5. An assay device according to any one of the preceding claims, wherein the test and/or reference flow paths comprise a label or indicator.
6. An assay device according to claim 5, wherein the label or indicator is mobilisable upon contact with the liquid sample.
7. An assay device according to claim 5 or 6, wherein the label or indicator is selected from the group consisting of: an enzyme; a fluorescent dye, a coloured dye; and a particle of colloidal gold or other metal.
8. An assay device according to any one of the preceding claims, wherein the assay device comprises a reagent which reacts with, or a binding partner which binds to, an analyte of interest present in the sample.
9. An assay device according to claim 8, wherein the reagent or binding partner is located in the test flow path.
10. An assay device according to claim 8 or 9, wherein the binding partner comprises an antibody, an antigen-binding fragment of an antibody, or a multimer of an antibody or an antigen-binding fragment thereof.
11. An assay device according to any one of claims 8, 9 or 10, wherein the reagent or binding partner is particulate or associated with a particle.
12. An assay device according to any one of claims 8-11, wherein the reagent or binding partner causes agglutination hi the presence of the analyte of interest, sufficient to impede or retard the flow of sample liquid along the test flow path.
13. An assay device according to any one of the preceding claims, further comprising an indicator region which indicates the result of the assay.
14. An assay device according to claim 13, wherein the indicator region is provided downstream of the junction region.
15. An assay device according to claim 13, wherein an indicator region is provided upstream of the junction region.
16. An assay device according to claim 15, wherein an indicator region is provided in both the test and the reference flow paths.
17. An assay device according to any one of the preceding claims, wherein one or more vents are provided downstream of the junction region, whereby displacement of air or other fluid through the vents is necessary to allow liquid to advance along the test and reference flow paths.
18. An assay device according to any one of the preceding claims, which provides a binary outcome for the assay result.
19. An assay device according to any one of the preceding claims, which is a pregnancy-testing device and the analyte of interest comprises hCG.
20. An assay device substantially as hereinbefore described and as illustrated in the accompanying drawings.
21. A method of detecting the presence and/or amount of an analyte of interest in a liquid sample, the method comprising the steps of: applying the liquid sample to the sample application region of an assay device in accordance with any one of the preceding claims; and noting or recording the assay result.
PCT/GB2007/003091 2006-08-30 2007-08-14 Fluidic indicator device WO2008025945A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2661065A CA2661065C (en) 2006-08-30 2007-08-14 Fluidic indicator device
CN200780038590.5A CN101528350B (en) 2006-08-30 2007-08-14 Fluidic indicator device
JP2009526157A JP5263624B2 (en) 2006-08-30 2007-08-14 Fluid indicator device
AU2007291058A AU2007291058B2 (en) 2006-08-30 2007-08-14 Fluidic indicator device
EP07789214.9A EP2056965B9 (en) 2006-08-30 2007-08-14 Fluidic indicator device

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0617035.1 2006-08-30
GBGB0617035.1A GB0617035D0 (en) 2006-08-30 2006-08-30 Fluidic indicator device

Publications (1)

Publication Number Publication Date
WO2008025945A1 true WO2008025945A1 (en) 2008-03-06

Family

ID=37137002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/003091 WO2008025945A1 (en) 2006-08-30 2007-08-14 Fluidic indicator device

Country Status (8)

Country Link
US (3) US20080076190A1 (en)
EP (1) EP2056965B9 (en)
JP (1) JP5263624B2 (en)
CN (1) CN101528350B (en)
AU (1) AU2007291058B2 (en)
CA (1) CA2661065C (en)
GB (1) GB0617035D0 (en)
WO (1) WO2008025945A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2101917A1 (en) * 2007-01-10 2009-09-23 Scandinavian Micro Biodevices A/S A microfluidic device and a microfluidic system and a method of performing a test
WO2009125227A1 (en) * 2008-04-12 2009-10-15 Spd Swiss Precision Diagnostics Gmbh Assay device comprising bubble-forming means
US20100267065A1 (en) * 2009-03-25 2010-10-21 Timothy Robert Geiger Apparatus and methods for analyzing fluid variables
WO2012164263A1 (en) 2011-06-01 2012-12-06 Carclo Technical Plastics Limited Capillary fluid flow measurment and capillary flow device therefore
US9797896B2 (en) 2013-02-12 2017-10-24 Ortho-Clinical Diagnostics, Inc. Reagent zone deposition pattern

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0617035D0 (en) * 2006-08-30 2006-10-11 Inverness Medical Switzerland Fluidic indicator device
US8222908B2 (en) * 2010-02-16 2012-07-17 Stratasys, Inc. Capacitive detector for use in extrusion-based digital manufacturing systems
EP2591358B1 (en) * 2010-07-05 2016-09-07 Koninklijke Philips N.V. Examination system with sample incubation
EP2916953B1 (en) * 2012-11-08 2023-03-29 Takara Bio USA, Inc. Extraction of restrained liquid from wells
US9386948B2 (en) 2012-12-05 2016-07-12 Theranos, Inc. Systems, devices, and methods for bodily fluid sample transport
US10248765B1 (en) 2012-12-05 2019-04-02 Theranos Ip Company, Llc Systems, devices, and methods for bodily fluid sample collection, transport, and handling
SG11201507325XA (en) 2013-03-15 2015-10-29 Theranos Inc Methods and devices for sample collection and sample separation
US20140323911A1 (en) * 2013-03-15 2014-10-30 Theranos, Inc. Methods and devices for sample collection and sample separation
US10073069B2 (en) 2013-04-23 2018-09-11 Cordant Research Solutions, Llc Systems and methods to determine body drug concentration from an oral fluid
WO2015138343A1 (en) 2014-03-10 2015-09-17 Click Diagnostics, Inc. Cartridge-based thermocycler
CN103983769B (en) * 2014-03-25 2015-11-18 中国海洋大学 A kind of preparation method of nm of gold immunochromatography kapillary
CN107429281B (en) 2014-12-31 2022-05-27 维斯比医学公司 Apparatus and method for molecular diagnostic testing
US10371606B2 (en) 2015-07-21 2019-08-06 Theraos IP Company, LLC Bodily fluid sample collection and transport
WO2017044888A1 (en) 2015-09-09 2017-03-16 Theranos, Inc. Methods and devices for sample collection and sample separation
WO2017185067A1 (en) 2016-04-22 2017-10-26 Click Diagnostics, Inc. Printed circuit board heater for an amplification module
WO2017197040A1 (en) 2016-05-11 2017-11-16 Click Diagnostics, Inc. Devices and methods for nucleic acid extraction
USD800331S1 (en) 2016-06-29 2017-10-17 Click Diagnostics, Inc. Molecular diagnostic device
CN110325652A (en) 2016-06-29 2019-10-11 易捷仪器诊断股份有限公司 Use the device and method of flow cell detection molecules
CA3029682A1 (en) * 2016-06-30 2018-01-04 Click Diagnostics, Inc. Devices and methods for nucleic acid extraction
USD800913S1 (en) 2016-06-30 2017-10-24 Click Diagnostics, Inc. Detection window for molecular diagnostic device
USD800914S1 (en) 2016-06-30 2017-10-24 Click Diagnostics, Inc. Status indicator for molecular diagnostic device
JP6819238B2 (en) * 2016-11-21 2021-01-27 株式会社デンソー Wiring abnormality detection device
US11857966B1 (en) 2017-03-15 2024-01-02 Labrador Diagnostics Llc Methods and devices for sample collection and sample separation
US11162130B2 (en) 2017-11-09 2021-11-02 Visby Medical, Inc. Portable molecular diagnostic device and methods for the detection of target viruses
US11198128B2 (en) * 2018-09-05 2021-12-14 International Business Machines Corporation Microfluidic device with array of chambers for encoding detectable information
CN113167760B (en) * 2018-12-02 2023-11-03 聚合物技术系统公司 Systems and methods for electronic gate features in electrochemical test strips
US11352675B2 (en) 2020-01-03 2022-06-07 Visby Medical, Inc. Devices and methods for antibiotic susceptability testing
US20210325386A1 (en) * 2020-04-15 2021-10-21 University Of Rochester Microfluidic Devices and Methods for Rapid Detection of Pathogens and Other Analytes
US11622886B2 (en) 2020-05-18 2023-04-11 Johnson & Johnson Surgical Vision, Inc. Thermocouple coupled with a piezoelectric crystal for feedback on vibration frequency
US11534752B2 (en) * 2020-12-30 2022-12-27 International Business Machines Corporation Rapid test device having multiple heterogeneous diagnostic methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083859A1 (en) * 2003-03-18 2004-09-30 Platform Diagnostics Limited Agglutination based sample testing device
US20050255004A1 (en) * 2004-04-29 2005-11-17 Nan-Kuang Yao Gravity-driven apparatus and method for control of microfluidic devices
WO2006046054A1 (en) * 2004-10-28 2006-05-04 Platform Diagnostics Limited Assay system

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963498A (en) 1985-08-05 1990-10-16 Biotrack Capillary flow device
JPH0746107B2 (en) 1987-04-27 1995-05-17 ユニリーバー・ナームローゼ・ベンノートシヤープ Test method
US5275785A (en) * 1987-10-30 1994-01-04 Unilever Patent Holdings B.V. Test device for detecting an analyte in a liquid sample
GB8903046D0 (en) 1989-02-10 1989-03-30 Vale David R Testing of liquids
IE69047B1 (en) * 1989-03-23 1996-08-07 Gary Harold Gregory Hen Thorpe Liquid transfer devices
WO1993022058A1 (en) 1992-05-01 1993-11-11 Trustees Of The University Of Pennsylvania Polynucleotide amplification analysis using a microfabricated device
US5308775A (en) * 1992-09-15 1994-05-03 Abbott Laboratories Assay devices for concurrently detecting an analyte and confirming the test result
US6991762B1 (en) 1996-04-26 2006-01-31 Arkray, Inc. Device for analyzing a sample
US6074827A (en) 1996-07-30 2000-06-13 Aclara Biosciences, Inc. Microfluidic method for nucleic acid purification and processing
US5804436A (en) 1996-08-02 1998-09-08 Axiom Biotechnologies, Inc. Apparatus and method for real-time measurement of cellular response
US6090251A (en) 1997-06-06 2000-07-18 Caliper Technologies, Inc. Microfabricated structures for facilitating fluid introduction into microfluidic devices
US6521182B1 (en) 1998-07-20 2003-02-18 Lifescan, Inc. Fluidic device for medical diagnostics
US6830934B1 (en) * 1999-06-15 2004-12-14 Lifescan, Inc. Microdroplet dispensing for a medical diagnostic device
US6637463B1 (en) 1998-10-13 2003-10-28 Biomicro Systems, Inc. Multi-channel microfluidic system design with balanced fluid flow distribution
GB9825992D0 (en) * 1998-11-28 1999-01-20 Moorlodge Biotech Ventures Lim Electrochemical sensor
US7040144B2 (en) 2000-02-23 2006-05-09 Caliper Life Sciences, Inc. Microfluidic viscometer
WO2001068238A2 (en) 2000-03-14 2001-09-20 Micronics, Inc. Microfluidic analysis cartridge
US6561208B1 (en) 2000-04-14 2003-05-13 Nanostream, Inc. Fluidic impedances in microfluidic system
US7524462B2 (en) 2002-03-29 2009-04-28 Agilent Technologies, Inc. Capillary flow for a heterogenous assay in a micro-channel environment
US7901939B2 (en) 2002-05-09 2011-03-08 University Of Chicago Method for performing crystallization and reactions in pressure-driven fluid plugs
US20040053315A1 (en) * 2002-08-12 2004-03-18 Caliper Technologies Corp. Methods and systems for monitoring molecular interactions
US7374546B2 (en) * 2003-01-29 2008-05-20 Roche Diagnostics Operations, Inc. Integrated lancing test strip
JP2006053090A (en) * 2004-08-13 2006-02-23 Alps Electric Co Ltd Inspection plate and inspection method using it
GB0617035D0 (en) * 2006-08-30 2006-10-11 Inverness Medical Switzerland Fluidic indicator device
EP2101917A1 (en) 2007-01-10 2009-09-23 Scandinavian Micro Biodevices A/S A microfluidic device and a microfluidic system and a method of performing a test

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083859A1 (en) * 2003-03-18 2004-09-30 Platform Diagnostics Limited Agglutination based sample testing device
US20050255004A1 (en) * 2004-04-29 2005-11-17 Nan-Kuang Yao Gravity-driven apparatus and method for control of microfluidic devices
WO2006046054A1 (en) * 2004-10-28 2006-05-04 Platform Diagnostics Limited Assay system

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2101917A1 (en) * 2007-01-10 2009-09-23 Scandinavian Micro Biodevices A/S A microfluidic device and a microfluidic system and a method of performing a test
WO2009125227A1 (en) * 2008-04-12 2009-10-15 Spd Swiss Precision Diagnostics Gmbh Assay device comprising bubble-forming means
US9151749B2 (en) 2008-04-12 2015-10-06 Alere Switzerland Gmbh Assay device comprising bubble-forming means
US20100267065A1 (en) * 2009-03-25 2010-10-21 Timothy Robert Geiger Apparatus and methods for analyzing fluid variables
CN102483410A (en) * 2009-03-25 2012-05-30 莱泽尔诊断公司 Apparatus and methods for analyzing fluid variables
US8481278B2 (en) * 2009-03-25 2013-07-09 Lyzer Diagnostics, Inc. Apparatus and methods for analyzing fluid variables
US20140024059A1 (en) * 2009-03-25 2014-01-23 Lyzer Diagnostics, Inc. Apparatus and methods for analyzing fluid variables
WO2012164263A1 (en) 2011-06-01 2012-12-06 Carclo Technical Plastics Limited Capillary fluid flow measurment and capillary flow device therefore
US9797896B2 (en) 2013-02-12 2017-10-24 Ortho-Clinical Diagnostics, Inc. Reagent zone deposition pattern
US9927436B2 (en) 2013-02-12 2018-03-27 Ortho-Clinical Diagnostics, Inc. Reagent zone deposition pattern

Also Published As

Publication number Publication date
CA2661065A1 (en) 2008-03-06
JP5263624B2 (en) 2013-08-14
CN101528350A (en) 2009-09-09
EP2056965B9 (en) 2013-11-06
AU2007291058B2 (en) 2014-03-06
US20080076190A1 (en) 2008-03-27
EP2056965A1 (en) 2009-05-13
US20140141501A1 (en) 2014-05-22
JP2010501876A (en) 2010-01-21
US8492136B2 (en) 2013-07-23
GB0617035D0 (en) 2006-10-11
AU2007291058A1 (en) 2008-03-06
US20120122234A1 (en) 2012-05-17
CA2661065C (en) 2014-07-15
EP2056965B1 (en) 2013-03-20
CN101528350B (en) 2012-11-14
US8980177B2 (en) 2015-03-17

Similar Documents

Publication Publication Date Title
EP2056965B1 (en) Fluidic indicator device
EP2673641B1 (en) Reduced step dual path immunoassay device and method
US9151749B2 (en) Assay device comprising bubble-forming means
US8614101B2 (en) In situ lysis of cells in lateral flow immunoassays
US7459127B2 (en) Method and apparatus for precise transfer and manipulation of fluids by centrifugal and/or capillary forces
EP1768783B1 (en) Controlled flow assay device and method
US6410341B1 (en) Analytical test device and method for use in medical diagnoses
JP2002522767A (en) Analytical test apparatus and method
JP2004536309A (en) Lateral flow immunoassay device
US20080148822A1 (en) Fluidic Gating Device
EP2313775A2 (en) In situ lysis of cells in lateral flow immunoassays
EP0443231A1 (en) Multi-layered diagnostic test device for the determination of substances in liquids
JP5139581B2 (en) Analytical strip
ES2435545T3 (en) A method to analyze a liquid
WO2006011249A1 (en) Analytical apparatus and method of analysis
EP2835645B1 (en) Lateral flow membrane and immunoassay device

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780038590.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07789214

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2007291058

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007789214

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2661065

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009526157

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007291058

Country of ref document: AU

Date of ref document: 20070814

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1871/DELNP/2009

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: RU